Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders

Overview

Journal Can J Psychiatry

Specialty Psychiatry

Date 2017 Sep 10

PMID 28886671

Citations 42

Authors

David Crockford

Donald Addington

Affiliations

Soon will be listed here.

Abstract

Objective: Persons with schizophrenia and other psychotic disorders frequently have coexisting substance use disorders that require modifications to treatment approaches for best outcomes. The objectives of this review were to identify evidence-based practices best practices that improve outcomes for individuals with schizophrenia and substance used disorders.

Method: We reviewed guidelines that were published in the last 5 years and that included systematic reviews or meta-analyses. Most of our recommendations came from 2 publications from the National Institute for Health and Care Excellence (NICE): the 2011 guidance titled Coexisting Severe Mental Illness (Psychosis) and Substance Misuse: Assessment and Management in Healthcare Settings and the 2014 guidance titled Psychosis and Schizophrenia in Adults: Prevention and Management. We placed these recommendations into the Canadian context to create this guideline.

Results: Evidence supports the inclusion of individuals with coexisting substance use disorders in first-episode psychosis programs. The programs should integrate psychosis and substance use treatments, emphasizing ongoing monitoring of both substance use and patterns and symptoms. The best outcomes are achieved with combined use of antipsychotic medications and addiction-based psychosocial interventions. However, limited evidence is available to recommend using one antipsychotic medication over another or one psychosocial intervention over another for persons with schizophrenia and other psychotic disorders with coexisting substance use disorders.

Conclusions: Treating persons who have schizophrenia and other psychotic disorders with coexisting substance use disorders can present clinical challenges, but modifications in practice can help engage and retain people in treatment, where significant improvements over time can be expected.

Citing Articles

The Association Between Antipsychotics and Bone Fragility: An Updated Comprehensive Review.

Mercurio M, Spina G, Galasso O, Gasparini G, Segura-Garcia C, De Fazio P Diagnostics (Basel). 2024; 14(23).

PMID: 39682653 PMC: 11640471. DOI: 10.3390/diagnostics14232745.

Effects of long-term antipsychotic medication on brain instability in first-episode schizophrenia patients: a resting-state fMRI study.

Zhong M, Liu Z, Wang F, Yang J, Chen E, Lee E Front Pharmacol. 2024; 15:1387123.

PMID: 38846088 PMC: 11153814. DOI: 10.3389/fphar.2024.1387123.

Key conditions for the successful implementation of evidence-based practice in concurrent disorder nursing care with the ECHO® model: Insights from a mixed-methods study.

Chicoine G, Cote J, Pepin J, Pluye P, Jutras-Aswad D Int J Nurs Stud Adv. 2024; 5:100153.

PMID: 38746592 PMC: 11080413. DOI: 10.1016/j.ijnsa.2023.100153.

Schizophrenia and schizoaffective disorder: Length of stay and associated factors.

Goga L, Marais B S Afr J Psychiatr. 2024; 30:2237.

PMID: 38726337 PMC: 11079426. DOI: 10.4102/sajpsychiatry.v30i0.2237.

Investigating the Effectiveness of Brexpiprazole in Subjects with Schizophrenia Spectrum Illness and Co-Occurring Substance Use Disorder: A Prospective, Multicentric, Real-World Study.

Chiappini S, Cavallotto C, Mosca A, Di Carlo F, Piro T, Giovannetti G Pharmaceuticals (Basel). 2024; 17(4).

PMID: 38675495 PMC: 11053971. DOI: 10.3390/ph17040535.

References

DiClemente C, Delahanty J, Kofeldt M, Dixon L, Goldberg R, Lucksted A . Stage movement following a 5A's intervention in tobacco dependent individuals with serious mental illness (SMI). Addict Behav. 2010; 36(3):261-4. PMC: 5694216. DOI: 10.1016/j.addbeh.2010.11.002. View

Olincy A, Young D, Freedman R . Increased levels of the nicotine metabolite cotinine in schizophrenic smokers compared to other smokers. Biol Psychiatry. 1997; 42(1):1-5. DOI: 10.1016/S0006-3223(96)00302-2. View

Tidey J, Miller M . Smoking cessation and reduction in people with chronic mental illness. BMJ. 2015; 351:h4065. PMC: 4707528. DOI: 10.1136/bmj.h4065. View

Moore T, Zammit S, Lingford-Hughes A, Barnes T, Jones P, Burke M . Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet. 2007; 370(9584):319-28. DOI: 10.1016/S0140-6736(07)61162-3. View

Brouwers M, Kho M, Browman G, Burgers J, Cluzeau F, Feder G . AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ. 2010; 182(18):E839-42. PMC: 3001530. DOI: 10.1503/cmaj.090449. View

Meis L, Griffin J, Greer N, Jensen A, MacDonald R, Carlyle M . Couple and family involvement in adult mental health treatment: a systematic review. Clin Psychol Rev. 2013; 33(2):275-86. DOI: 10.1016/j.cpr.2012.12.003. View

Williams J, Anthenelli R, Morris C, Treadow J, Thompson J, Yunis C . A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2012; 73(5):654-60. DOI: 10.4088/JCP.11m07522. View

Thomas K, Martin R, Knipe D, Higgins J, Gunnell D . Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis. BMJ. 2015; 350:h1109. PMC: 4357491. DOI: 10.1136/bmj.h1109. View

Large M, Sharma S, Compton M, Slade T, Nielssen O . Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch Gen Psychiatry. 2011; 68(6):555-61. DOI: 10.1001/archgenpsychiatry.2011.5. View

10.

Marshall K, Gowing L, Ali R, Le Foll B . Pharmacotherapies for cannabis dependence. Cochrane Database Syst Rev. 2014; (12):CD008940. PMC: 4297244. DOI: 10.1002/14651858.CD008940.pub2. View

11.

Mcloughlin B, Pushpa-Rajah J, Gillies D, Rathbone J, Variend H, Kalakouti E . Cannabis and schizophrenia. Cochrane Database Syst Rev. 2014; (10):CD004837. PMC: 10107010. DOI: 10.1002/14651858.CD004837.pub3. View

12.

Brunette M, Mueser K . Psychosocial interventions for the long-term management of patients with severe mental illness and co-occurring substance use disorder. J Clin Psychiatry. 2006; 67 Suppl 7:10-7. View

13.

Green A, Brunette M, Dawson R, Buckley P, Wallace A, Hafez H . Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry. 2015; 76(10):1359-65. DOI: 10.4088/JCP.13m08838. View

14.

Kessler R, Nelson C, McGonagle K, Edlund M, Frank R, Leaf P . The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatry. 1996; 66(1):17-31. DOI: 10.1037/h0080151. View

15.

Margolese H, Malchy L, Negrete J, Tempier R, Gill K . Drug and alcohol use among patients with schizophrenia and related psychoses: levels and consequences. Schizophr Res. 2004; 67(2-3):157-66. DOI: 10.1016/S0920-9964(02)00523-6. View

16.

Drake R, ONeal E, Wallach M . A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. J Subst Abuse Treat. 2007; 34(1):123-38. DOI: 10.1016/j.jsat.2007.01.011. View

17.

Arendt M, Mortensen P, Rosenberg R, Pedersen C, Waltoft B . Familial predisposition for psychiatric disorder: comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry. 2008; 65(11):1269-74. DOI: 10.1001/archpsyc.65.11.1269. View

18.

Lubman D, King J, Castle D . Treating comorbid substance use disorders in schizophrenia. Int Rev Psychiatry. 2010; 22(2):191-201. DOI: 10.3109/09540261003689958. View

19.

Tsoi D, Porwal M, Webster A . Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev. 2013; (2):CD007253. PMC: 6486303. DOI: 10.1002/14651858.CD007253.pub3. View

20.

Brunette M, Mueser K, Drake R . A review of research on residential programs for people with severe mental illness and co-occurring substance use disorders. Drug Alcohol Rev. 2005; 23(4):471-81. DOI: 10.1080/09595230412331324590. View